Metformin Crescent Pharma (Metformin Hydrochloride)

Metformin Crescent Pharma is a biguanide indicated for disorders of glucose metabolism.

• Type 2 diabetes mellitus: lowers fasting and post‑prandial blood glucose levels to improve glycaemic control.
• Prediabetes (impaired glucose tolerance): delays progression to overt diabetes by enhancing insulin sensitivity.
• Polycystic ovary syndrome: reduces insulin resistance and may help normalize menstrual cycles.

• Metformin Hydrochloride acts primarily by inhibiting mitochondrial respiratory‑chain complex I, which decreases hepatic gluconeogenesis. It also increases peripheral glucose uptake and utilization by activating AMP‑activated protein kinase (AMPK), thereby improving insulin sensitivity without stimulating insulin secretion.

Metformin Crescent Pharma may cause a range of adverse reactions.

Common Side Effects

• Gastrointestinal upset: nausea, abdominal discomfort, or diarrhoea.
• Metallic taste: transient alteration in taste perception.
• Weight loss: modest reduction in body weight in some patients.

Serious or Rare Side Effects

• Lactic acidosis: rare but potentially fatal metabolic disturbance.
• Vitamin B12 deficiency: may develop with long‑term therapy.
• Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis.

When prescribing Metformin Crescent Pharma, consider the following safety measures.

• Renal function: assess creatinine clearance before initiation and periodically thereafter.
• Hepatic impairment: avoid use in patients with significant liver disease.
• Cardiovascular status: monitor for signs of heart failure, especially during acute illness.
• Alcohol consumption: advise patients to limit intake to reduce lactic acidosis risk.
• Pregnancy and lactation: evaluate risk‑benefit ratio; use only if clearly needed.
• Store at ambient temperature: keep below 25°C in the original container, protect from moisture and light.

Metformin Crescent Pharma can interact with several medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid)

• Iodinated contrast agents: may precipitate acute renal failure, increasing lactic acidosis risk.
• Cimetidine: can raise metformin plasma concentrations.

Moderate Interactions (Monitor Closely)

• ACE inhibitors or ARBs: may enhance renal effects, monitor kidney function.
• Beta‑blockers: may mask hypoglycaemia symptoms.
• Diuretics: can affect renal clearance of metformin.
• Alcohol: potentiates lactic acidosis risk.
• Antiretroviral agents (e.g., protease inhibitors): may increase metformin levels.